DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Pfizer to acquire Arena Pharma; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts clinical data; Roche unveils Avenio system Visit Post
2 AstraZeneca-Moderna's AZD8601 VEGF-A mRNA Trial; Wision AI gets CE Mark approval; Getinge acquires Verrix; LumiThera buys Diopsys Visit Post
3 Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding Visit Post
4 Biogen's ALS drug Tofersen (BIIB067); Phathom's erosive esophagitis drug trial; Vertex's islet cell therapy; Natera launches lung DNA test Visit Post
5 Analyzing the Emerging Demand for the Probiotics Visit Post
6 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
7 Novel Therapies form the Nucleus of the Growth in the Crohn's Disease Therapeutic Market Visit Post
8 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
9 Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products Visit Post
10 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
11 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
12 Adagio Raises $336 M; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy Visit Post
13 Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market Visit Post
14 How Robots Are Introducing A New Dimension To Healthcare Service Delivery Visit Post
15 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
16 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
17 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
18 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
19 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
20 The State of Alternative Medicine In The Healthcare Visit Post
21 Healthcare Delivery System: What lies in the future? Visit Post
22 What Can Help Manage The Insufficient Pancreas? Visit Post
23 Nutrition Intervention: Foods to take and foods to avoid when suffering from Gastroparesis Visit Post
24 New Hopes; New Horizons: Gastroparesis Market Has Mighty Treatment Options On Its Sleeves Visit Post
25 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
26 Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Visit Post
27 FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing Visit Post
28 Dubai: A leading and exciting pharma hotspot Visit Post
29 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
30 Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod Visit Post
31 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
32 AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development Visit Post
33 Rapt Therapeutics files IPO; Novartis stakes $80M for NASH Visit Post
34 Global Burden of Liver cancer: Is it rising?  Visit Post
35 FDA approves Ibsrela to reduce the global burden of Irritable Bowel Syndrome Visit Post
36 What lies in the future for NASH upcoming drugs? Visit Post
37 GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre Visit Post
38 Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact Visit Post
39 Diabetic Gastroparesis Market Outlook Visit Post
40 EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline Visit Post
41 Hernia Awareness Month Visit Post
42 Notizia Visit Post
43 NASH Emerging Therapies Visit Post
44 Off-label therapies dominate NASH Market Share Visit Post
45 Recent Market Reports Visit Post
46 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
47 Current and Emerging therapies that change Traveler’s Diarrhea Market Visit Post
48 Global Traveler's Diarrhea Market Visit Post
49 Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial Visit Post
50 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
51 Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal Visit Post
52 Newsletter Visit Post
53 Notizia Visit Post
54 Notizia Visit Post
55 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
56 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
57 Can GABA turn pancreatic α-cells into β-cells? Visit Post
58 Notizia Visit Post
59 Commercial Outcomes - Novartis Visit Post
60 Takeda buys Shire in a deal worth USD 62 billion Visit Post
61 Takeda acquisition on Shire raises its share by 25 percent Visit Post
62 Nonalcoholic Steatohepatitis (NASH): Highly Epidemic Visit Post
63 Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH) Visit Post
64 Business Cocktail Visit Post
65 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
66 Epidemiology: Fatty Liver Disease Visit Post
67 Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation Visit Post
68 Microbiome- A Living Therapy from Guts to Cancer Visit Post
69 Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal Visit Post
70 Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan's MAA accepted; Pricing hit pharma Visit Post
71 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
72 Bayer AG & Evotec AG’s deal; Plasticell and CellSpring AG’s deal; Allergan Acquires Akarna; Cambrex Acquires Pharmacore Visit Post
73 DelveInsight’s Gastrointestinal based Gene Therapy Reports Visit Post